Pfizer Finance VP Denton Leaves to Become Nike’s CFO
PFE•Pfizer finance vice president Linda Denton has been appointed as Nike’s next chief financial officer, creating a leadership vacancy at Pfizer later this year. Denton’s departure comes as Pfizer prepares for key drug approvals and refines its 2026 revenue guidance.
1. CFO Transition
Pfizer finance vice president Linda Denton will depart Pfizer to assume the role of chief financial officer at Nike, effective in the fourth quarter of 2026. Denton has led Pfizer’s global finance operations for the past six years and oversaw budgeting, forecasting and investor relations during the rollout of its vaccine portfolio.
2. Implications for Pfizer
Denton’s exit leaves a gap in Pfizer’s senior finance leadership as the company approaches regulatory decisions on its oncology and rare disease drugs. Pfizer’s board has initiated a search for a successor and may appoint an interim finance chief to manage upcoming earnings guidance and capital allocation decisions.
